Novel strategies for lipid-independent atherosclerosis intervention

Keywords

Atherosclerosis / Lipid-independent / P2RY6 / CYSLTR2 / Intervention strategy

Ethical statements

Not applicable.

Author contributions

The authors confirm their contributions to the paper as follows: conceptualization: Hu Q; writing of this manuscript: Li Y, Zhang C, Zhou Y; revision of this manuscript: Hu Q, Li Y, Zhang C, Zhou, Y, Lauschke VM. All authors reviewed the results and approved the final version of the manuscript.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Acknowledgements

This work was supported by the National Key Research and Development Program of China (Grant No. 2023YFC2812500 to Qinghua Hu).

Conflict of Interest

Volker M. Lauschke is co-founder, CEO and shareholder of HepaPredict AB, as well as co-founder and shareholder of Shanghai Hepo Biotechnology Ltd. The other authors declare no competing interests.

References

[1] Khan AW, Jandeleit-Dahm KAM. 2025. Atherosclerosis in diabetes melli-tus: novel mechanisms and mechanism-based therapeutic approaches. Nature Reviews Cardiology 22( 7):482-496

[2] Crunkhorn S. 2025. Blocking ceramide signalling alleviates atheroscle-rosis. Nature Reviews Drug Discovery 24( 5):334

[3] Zhang S, Lin H, Wang J, Rui J, Wang T, et al. 2025. Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis. Nature 641:476-485

[4] Zhu Q, Scherer PE. 2024. Ceramides and atherosclerotic cardiovascular disease: a current perspective. Circulation 149(21):1624-1626

[5] Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. 2021. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nature Reviews Cardiology 18( 10):701-711

[6] Blackburn MR. 2011. P2Y6 and vascular inflammation. Blood 117(8):2304-2305

[7] Li Y, Zhou M, Li H, Dai C, Yin L, et al. 2024. Macrophage P2Y 6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways. European Heart Journal 45( 4):268-283

[8] Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, et al. 2021. G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduction and Targeted Therapy 6( 1):7

[9] Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, et al. 2016. Recur-rent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics 48(6):675-680

[10] de Almeida Carvalho L, Alves VS, Coutinho-Silva R, Savio LEB. 2025. G protein-coupled purinergic P2Y receptors in infectious diseases. Phar-macology & Therapeutics 267:108796

[11] Zhu Y, Zhou M, Cheng X, Wang H, Li Y, et al. 2023. Discovery of selective P2Y6R antagonists with high affinity and in vivo efficacy for inflammatory disease therapy. Journal of Medicinal Chemistry 66( 9):6315-6332

[12] Wright SC, Motso A, Koutsilieri S, Beusch CM, Sabatier P, et al. 2023. GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics. Nature Communications 14(1):6243